30 closest matches · ranked by relevance
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
Breast Cancer
Primary: Progression-free Survival (PFS) — 14.4; 19.3 Months
Breast Cancer
Primary: Median Progression Free Survival (PFS) — 7.2 months
Breast Cancer
Primary: Overall Response Rate (ORR) — 35.6; 13.2 percentage of participants — p=0.42
HER2 Positive Breast Cancer · Left Ventricular Function Systolic Dysfunction
Primary: Percentage of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function. — 27 Participants
Breast Cancer
Primary: Pathological Response for Basal Group 2 — 16; 14; 5; 11 Participants
Malignant Neoplasm of Female Breast
Primary: Overall Response Rate — 25; 21 Participants
Breast Cancer
Primary: Pathologic Complete Response Rate After Preoperative Therapy With Cisplatin and Bevacizumab in ER-, PR-, Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early…
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Estrogen Receptor Positive Breast Cancer
Primary: Ki67 Expression — 15; 10 Percentage of cells with Ki67 expression — p==0.0023
Breast Cancer
Primary: Number of Participants With Disease-free Survival (DFS) Event — 127; 170 Participants
Metastatic Beast Cancer
Primary: Progression-free Survival (PFS) Rate at 3 Months — 50.1 percent of participants
Breast Cancer
Primary: Invasive Disease-free Survival (DFS) — 42; 47 Participants
Metastatic Breast Cancer
Primary: Percentage of Patients With a 2 Year Disease-Free Survival (DFS) as a Measure of Efficacy — 56; 83; 73 percentage of patients
Breast Cancer · Carcinoma of the Breast
Primary: 3-year Disease Free Survival (DFS) Rate — 0.987 proportion of participant
Neoplasms, Breast
Primary: Overall Tumor Response — 1; 8; 18; 29 participants
HER2 Positive Breast Carcinoma · Stage IV Breast Cancer AJCC v6 and v7
Primary: Percent of Participants With Grade 2 or Higher Toxicities — 80 percentage of participants
Breast Cancer
Primary: Percentage of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) and Silver In-Situ…
Advanced Breast Cancer · Breast Cancer
Primary: Progression Free Survival — 4.53; 6.83 months — p=0.231
Breast Cancer
Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010
Breast Cancer
Primary: The Residual Cancer Burden Grade III (RCB-III). — 23; 37; 14; 6 Participants
Breast Cancer · Adjuvant Therapy · HER2-positive Breast Cancer
Primary: Description of Age — 49.2 years
Breast Cancer
Primary: Pathological Complete Response Rates at Surgery — 16; 2 participants
Breast Cancer
Primary: The Objective Response Rate as Defined as Stable Disease or the Rate of Complete and Partial Responses Determined on Two Consecutive Occasions Greater Than or Equal to 4…
Estrogen Receptor Positive Tumor · Breast Cancer
Primary: Percentage of Participants Who Achieved the Target Relative Dose Intensity (RDI) of 85% — 77.6; 90.0 Percentage of participants — p=0.1080
Breast Neoplasm
Primary: Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule — 60 percentage of participants
Breast Cancer · Metastasis
Primary: Number of Participants With Objective Response — 0; 1; 1; 1 participants
Breast Cancer
Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants
Breast Neoplasms
Primary: Part I Only: Clinical Benefit Rate (CR+PR+SD≥6months) of Patients Who Received Neratinib Alone — 5 Participants
Breast Cancer Metastases · HER2 Positive Breast
Primary: Percentage of Patients With HER2- Primary Breast Cancer Who Develop Imagable HER2+ Metastases — 13 % of participants